The natural lead compounds identified through the modern CADD approaches will be able to reduce the overexpression of the BET protein and, subsequently, the overexpression of MYCN proto-oncogene, resulting in hindering the activity of the neuroblastoma and related disease. This evidence concerns the gene MYCN and neuroblastoma.